

ASX/ Media Release  
16 October 2017

## Progress Update on Global Pancreatic Cancer Clinical Study Programme

**Sydney, Australia, 16 October 2017:** OncoSil Medical Limited (ASX: OSL) (**OncoSil Medical** or the **Company**) a medical device company focused on localised treatments for patients with pancreatic and liver cancer, is pleased to provide an update on the progress of its Global Pancreatic Cancer Clinical Study Programme.

### Highlights

- 28 subjects now recruited into current study group, up from 23 subjects on 22 September
- 14 subjects in study group successfully implanted with OncoSil™ device
- OncoSil will share interim data for the first time at the European Association of Nuclear Medicine on 21 October and will update the market accordingly
- The European Association of Nuclear Medicine is the largest organisation dedicated to Nuclear Medicine in Europe
- OncoSil advises notice of its 2017 Annual General Meeting on 25 October

OncoSil Chief Executive Officer Daniel Kenny commented:

*"I am pleased with the ongoing recruitment of our participating study centres, who remain diligent in their efforts, as we advance closer towards providing the requested 20 patient supplemental data for CE Mark certification. We look forward to updating the market with interim data from the study, for the first time, shared at the upcoming Annual Congress of the European Association of Nuclear Medicine."*

OncoSil continues to progress recruitment of its Global Pancreatic Cancer Clinical Study programme, announcing 28 subjects are now enrolled into the study group, up from 23 patients on 22 September. Of the study group, 14 subjects are now successfully implanted with OncoSil™ device.

OncoSil's Chief Medical Officer, Dr. Ashish Soman, will be presenting early data from the study at the Annual Congress of the European Association of Nuclear Medicine in Vienna on 21 October. The Company will share an update with the market accordingly.

Further, the Company advises it will hold its Annual General Meeting ("AGM") on Wednesday, 25 October 2017 at 11:00 AM (AEDT). The AGM will take place at:

The Offices of K & L Gates  
Level 31, 1 O'Connell St  
Sydney, NSW

- ENDS -

Company	Media
<b>Mr Daniel Kenny</b> CEO & Managing Director E: <a href="mailto:daniel.kenny@oncosil.com.au">daniel.kenny@oncosil.com.au</a> T: +61 2 9223 3344	<b>Ben Walsh</b> WE Buchan E: <a href="mailto:bwalsh@buchanwe.com.au">bwalsh@buchanwe.com.au</a> M: 0411 520 012

#### About OncoSil

OncoSil Medical is a medical device company seeking to advance radiation for cancer patients. OncoSil Medical's lead product, OncoSil™ is a targeted radioactive isotope (Phosphorous-32), implanted directly into a patient's pancreatic tumours via an endoscopic ultrasound.

Treatment with OncoSil™ is intended to deliver more concentrated and localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical studies with encouraging results on tolerability, safety and efficacy. A CE Mark application to commercially sell OncoSil™ in the European Union (EU) is under review with commercial launch, subject to approval.

An Investigational Device Exemption (IDE) has been granted by the United States Food and Drug Administration (FDA) to conduct a clinical study of the OncoSil™ device aimed at supporting a PMA approval. Pancreatic cancer is typically diagnosed at a later stage, when there is a poor prognosis for long-term survival. The World Cancer Research Fund estimated that in 2012, 338,000 people globally were diagnosed with pancreatic cancer. The prognosis for patients diagnosed with pancreatic cancer, regardless of stage, is generally poor; the relative five-year survival rate for all stages combined is approximately 5%. The estimated world-wide market opportunity for OncoSil™ in pancreatic cancer exceeds \$1b.

Hepatocellular carcinoma (HCC) or liver cancer, is the 6th most common cancer in the world with 782,000 new cases diagnosed in 2012. While hepatocellular carcinoma can be treated by surgery or transplantation, the majority of patients with HCC have disease which is too advanced for surgery and their survival ranges from a few months to two or more years. The value of the hepatocellular cancer market is expected to triple in size to \$1.4b by 2019.